-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 12, Enhua Pharmaceutical submitted and accepted the clinical application of a new drug for NH600001 Emulsion Injection.
Figure 1: New drugs declared by Enhua since 2021
Source: CDE official website
According to data from Mi Nei.
Table 1: Enhua's sales of over 100 million varieties in 2020
Source: Mi Nei.
Table 2: The latest progress of Enhua Class 1 new drugs that have been approved for clinical use
Source: Meinenet MED2.
In recent years, Enhua has implemented the strategy of creating and imitating and emphasizing both innovation and imitation, and has continuously increased its R&D investment in innovative drugs and high-policy and high-tech barrier generic drugs
Table 3: Enhua's other self-innovated class 1 new drugs under research
Source: Company's semi-annual report
In addition, according to Enhua's 2021 semi-annual report, the company currently has a number of independently innovative Class 1 new drugs under development.
Source: CDE official website, Minet database
The review data statistics are as of October 13, if there are any errors or omissions, please correct me